ArticleDiscover oncology2026
Expression of CSNK1D in lung adenocarcinoma and its prognostic value after surgery.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCSNK1D is a member of the CK1 family and is characterized by high conservation and widespread expression. It plays a regulatory role in the maintenance of numerous cellular processes and is expressed at low levels in normal tissues but is overexpressed in several types of cancer. All tumor tissues were pathologically diagnosed as lung adenocarcinoma.
methodsImmunohistochemistry (IHC) was used to retrospectively assess CSNK1D expression levels in 90 lung adenocarcinoma surgical tumor tissue microarrays (TMAs). All tumor tissues were pathologically diagnosed as lung adenocarcinoma. An enzyme-linked immunosorbent assay (ELISA) was employed to detect CSNK1D expression in serum samples from 22 lung adenocarcinoma patients. All tumor tissues were pathologically diagnosed as lung adenocarcinoma
resultsCSNK1D was expressed in both the cytoplasm and nucleus, with higher levels in tumor tissues than in adjacent nontumor tissues. The results of survival analysis revealed that high CSNK1D expression was significantly associated with a favorable prognosis. The results of multivariate analysis, adjusted for clinicopathological features, indicated that high CSNK1D expression was an independent predictor of cancer-specific survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.